OPTI and OPTH Related Headlines
Go Back- Optimi Health exports psilocybin to UK for phase 2 clinical trial
- Optimi Health ships first psilocybin export to UK for phase 2 trial
- Optimi Health exports psilocybin to UK for phase 2 clinical trial
- Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
- Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
- Australia expands psychedelic therapy access with updated prescriber rules
- Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
- Optimi Health prices $15 million offering, lists on NASDAQ
- Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
OPTI and OPTH Related Press Releases
Go Back- Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
- Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
- Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
- Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
